e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel clinical insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Tobias Lange (Regensburg, Germany), Tobias Lange, Michael Arzt, Michael Pfeifer
Source:
International Congress 2015 – Pulmonary hypertension: novel clinical insights
Session:
Pulmonary hypertension: novel clinical insights
Session type:
Poster Discussion
Number:
2101
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tobias Lange (Regensburg, Germany), Tobias Lange, Michael Arzt, Michael Pfeifer. Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?. Eur Respir J 2015; 46: Suppl. 59, 2101
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia.
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy?
Source: Annual Congress 2005 - News about pulmonary embolism
Year: 2005
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019
Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
Source: Eur Respir J, 55 (5) 2000700; 10.1183/13993003.00700-2020
Year: 2020
Diagnosis and treatment of secondary pulmonary hypertension in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 404s
Year: 2006
Combined treatment in pulmonary hypertension
Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine
Year: 2016
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008
Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008
Audit of disease targeted therapies in adult patients with pulmonary arterial hypertension
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era
Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension
Year: 2018
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Does pulmonary hypertension exclude pulmonary rehabilitation in patients with COPD?
Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept